Edition:
India

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

3.13USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$3.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,871
52-wk High
$5.00
52-wk Low
$2.75

Chart for

About

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates,... (more)

Overall

Beta: 2.98
Market Cap(Mil.): $36.27
Shares Outstanding(Mil.): 7.51
Dividend: --
Yield (%): --

Financials

BRIEF-Tonix Pharmaceuticals To Present FDA Breakthrough Therapy Designated PTSD Program At Microcap Conference

* DESIGNATED PTSD PROGRAM AT THE MICROCAP CONFERENCE IN NEW YORK

04 Apr 2018

BRIEF-Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data

* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 TRIAL OF FDA-DESIGNATED BREAKTHROUGH THERAPY TONMYA® (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR THE TREATMENT OF PTSD

03 Apr 2018

BRIEF-Tonix Pharma Reports Q4 Loss Per Share $0.71

* TONIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE

12 Mar 2018

BRIEF-Baker Bros Advisors LP Reports 8.9 Pct Passive Stake In Tonix Pharmaceuticals Holding As Of Dec 31, 2017 - SEC Filing

* BAKER BROS ADVISORS LP REPORTS 8.9 PERCENT PASSIVE STAKE IN TONIX PHARMACEUTICALS HOLDING AS OF DEC 31, 2017 - SEC FILING Source text: (http://bit.ly/2HcDj6B) Further company coverage:

14 Feb 2018

BRIEF-Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya

* TONIX PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE FOR NEW U.S. PATENT FOR THE ACTIVE INGREDIENT IN TONMYA (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) Source text for Eikon: Further company coverage:

23 Jan 2018

BRIEF-Tonix Pharmaceuticals Appoints Jessica Morris As CEO

* TONIX PHARMACEUTICALS APPOINTS JESSICA MORRIS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

09 Jan 2018

BRIEF-Tonix Pharmaceuticals Completes Positive Pre-Ind Meeting With FDA For TNX-102 SL

* TONIX PHARMACEUTICALS COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR TNX-102 SL (CYCLOBENZAPRINE HCI SUBLINGUAL TABLETS) AS A CLINICAL CANDIDATE FOR AGITATION IN ALZHEIMER’S DISEASE

12 Dec 2017

BRIEF-Tonix Pharmaceuticals Q3 loss per share $0.77

* Tonix Pharmaceuticals reports third quarter 2017 financial results and provides programs update

07 Nov 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.71 -0.48
Pfizer Inc. (PFE.N) $36.72 -0.34
Novartis AG (NOVN.S) CHF75.00 -0.76
AstraZeneca plc (AZN.L) 4,975.50 -14.00
GlaxoSmithKline plc (GSK.L) 1,410.40 -51.80

Earnings vs. Estimates